Evidence map›Paper›PMID 40197363›Full record

ArticleJCI insight2025

Early treatment and PD1 inhibition enhance HIV-specific functionality of follicular CD8+ T cells.

Susanne Rueger, Eva Gruener, Danni Wang, Faiaz Shaik Abdool, Veronica Ober, Theresa Vallée, Renate Stirner, Raffaele Conca, Immanuel Andrä, Lisa Rogers and 19 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Susanne RuegerDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Eva GruenerDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Danni WangGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Faiaz Shaik AbdoolAfrica Health Research Institute (AHRI), and.
Veronica OberDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Theresa ValléeGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Renate StirnerDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Raffaele ConcaDepartment of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Munich, Germany.
Immanuel AndräInstitute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.
Lisa RogersGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Robert ZahnDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital, LMU Munich, Munich, Germany.
Elke GersbacherMUC Research, Clinical Research, Munich, Germany.
Joanna EgerZentrum fuer Innere Medizin und Infektiologie, Munich, Germany.
Ramona PauliMVZ am Isartor, Munich, Germany.
Nils Postelprinzmed, Practice for Infectiology, Munich, Germany.
Christoph D SpinnerTUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany.
Jörg J VehreschildMedical Department 2, Hematology/Oncology and Infectious Diseases, University Hospital of Frankfurt, Frankfurt, Germany.
Melanie StecherUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany.
Hans NitschkoMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, and.
Josef EberleGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Johannes R BognerDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Ulrich SeyboldDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Rika DraenertDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Al LeslieAfrica Health Research Institute (AHRI), and.
Henrik N KløverprisAfrica Health Research Institute (AHRI), and.
Christof GeldmacherGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Maximilian MuenchhoffGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Kathrin HeldGerman Centre for Infection Research (DZIF), partner site Munich, Germany.
Julia RoiderDepartment of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
Gates Foundation INV-033558NIAID NIH HHS UM1 AI164566Wellcome Trust
6 · The paper itself

Abstract

People living with HIV treated during acute infection are the group for whom achieving functional cure appears most viable. Follicular CD8+ T cells could contribute to HIV reservoir clearance by accessing B cell follicles through CXCR5 expression. This study examines peripheral follicular CD8+ T cells using flow cytometry, transcriptome analyses, and functional assays in people treated during acute (n = 37) and chronic (n = 18) infection, as well as in individuals naturally controlling HIV (n = 20) and living without HIV (n = 10). Our results reveal that early, as opposed to late, treatment initiation preserves antiviral effector functions of follicular CD8+ T cells, which are further enhanced by PD1 inhibition. We also identify a correlation between follicular CD8+ T cells and intact proviral HIV DNA levels in acute, but not chronic, infection. Longitudinal transcriptomic analysis of peripheral effector cells after 48 weeks of suppressive therapy indicated traits of recent antigen exposure, suggesting potential recirculation into lymphoid tissue. These findings underscore the pivotal role of follicular CD8+ T cells in anti-HIV responses and support investigating targeted cure strategies, such as anti-PD1 therapy, especially in individuals initiating treatment during acute infection.

Indexed as

CD8-Positive T-LymphocytesHIV-1HIV InfectionsProgrammed Cell Death 1 ReceptorAdultFemaleHumansMaleMiddle AgedReceptors, CXCR5CXCR5 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CXCR5Adaptive immunityAIDS/HIVImmunologyT cells

Identifiers

PMID40197363
PMCPMC11981630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.